Local 12: Benefits of DHA supplements in pregnant women
UC researchers find DHA supplements in pregnant women decrease preterm births
Pregnant women may benefit from taking a nutritional supplement, docosahexaenoic acid (DHA), which is commonly found in fish and fish oil supplements, according to a study from researchers at the University of Kansas and the University of Cincinnati.
Early preterm births may be dramatically decreased with DHA supplements, with a dose of 1000 mg more effective for pregnant women with low DHA levels than the 200 mg found in some prenatal supplements, according to the study published in EClinicalMedicine, a clinical journal of The Lancet.
“Currently it is recommended for pregnant women to take 200 mg daily of DHA during pregnancy, which is included in most prenatal vitamins,” says Emily DeFranco, DO, professor and director of maternal-fetal medicine in the University of Cincinnati College of Medicine Department of Obstetrics and Gynecology.
DeFranco spoke about the research on WKRC-TV in Cincinnati for a Sunday morning segment. (Segment starts at 9:13.)
Emily DeFranco, DO
“However, we suspected that a higher dose of DHA would provide additional health benefits to pregnant women and help protect them from delivering early,” says DeFranco. “Preterm delivery is defined as giving birth at less than 37 weeks, with the due date being at 40 weeks. Preterm birth is a major public health burden, with the worst outcomes occurring in infants who deliver early preterm at less than 34 weeks. In this study, we wanted to see if women who took a higher dose of DHA during pregnancy would be less likely to deliver early preterm compared to women who took the standard recommended dose of 200 mg.”
The study included 1,100 women in a randomized trial conducted at the University of Kansas, the University of Cincinnati and Ohio State University. The study participants were healthy pregnant women who were randomly assigned to take a daily DHA supplement of either 200 mg or 1000 mg.
“Our goal was to determine whether taking a higher dose of DHA during pregnancy resulted in a reduced risk of having an early preterm delivery at less than 34 weeks of pregnancy,” says DeFranco, a co-author of the study. “Pregnant women should take DHA. This study tells us that many women benefit from taking a higher dose of DHA supplement in pregnancy, especially those who don't eat a lot of foods high in DHA like fish and eggs.”
A second segment on the study is also available from WKRC online.
Featured image courtesy of Unsplash.
Next Lives Here
The University of Cincinnati is leading public urban universities into a new era of innovation and impact. Our faculty, staff and students are saving lives, changing outcomes and bending the future in our city's direction. Next Lives Here.
Stay up to date on all UC's COVID-19 stories, or take a UC virtual visit and begin picturing yourself at an institution that inspires incredible stories.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.